Kendall Capital Management Invests $6.25 Million in AbbVie Inc. $ABBV

Kendall Capital Management purchased a new stake in AbbVie Inc. (NYSE:ABBV) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 24,818 shares of the company’s stock, valued at approximately $6,245,000. AbbVie accounts for approximately 1.0% of Kendall Capital Management’s portfolio, making the stock its 23rd biggest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vista Investment Management acquired a new position in AbbVie during the second quarter worth $306,000. Hudson Portfolio Management LLC purchased a new position in AbbVie during the second quarter valued at $393,000. Compass Financial Management LLC acquired a new stake in shares of AbbVie in the second quarter valued at about $2,757,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of AbbVie during the second quarter worth about $23,175,000. Finally, Alta Advisers Ltd purchased a new stake in shares of AbbVie during the second quarter worth about $1,702,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ABBV. Canaccord Genuity Group increased their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Cantor Fitzgerald lifted their price target on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Guggenheim boosted their price target on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Wells Fargo & Company increased their price objective on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Finally, BMO Capital Markets raised their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $275.95.

AbbVie Stock Performance

Shares of AbbVie stock opened at $261.50 on Thursday. The firm has a market capitalization of $462.02 billion, a price-to-earnings ratio of 73.87, a PEG ratio of 1.18 and a beta of 0.29. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The stock has a 50 day moving average of $254.23 and a 200 day moving average of $229.67.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the firm earned $2.97 EPS. AbbVie’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.